Dr. Mike Evans, who has been with Ampersand since 2018, is a seasoned Board member with extensive experience in Life Science and In-Vitro Diagnostics (IVD). Mike is currently a Director at Ampersand portfolio company Tjoapack and most recently served as a Director at GenDx. Mike was formerly CEO of Oxford Gene Technology (OGT) for 13 years, where he led the company’s transformation from a licensing-led business model to a highly successful genomic products business before its sale to Sysmex Corporation in 2017. Before joining OGT, Mike held a number of senior positions at GE Healthcare/Amersham Biosciences and Ascot plc. Mike has also held several Non-Executive Directorships and was Chairman of TAP Biosystems Group plc until its sale to Sartorius Stedim Biotech. Mike obtained a B.A., M.A., and Ph.D. in Biochemistry from Oxford University.